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Abstract 30 
Antimicrobial peptides (AMPs) are gaining popularity as alternatives for treatment of bacterial 31 
infections and recent advances in omics technologies provide new platforms for AMP 32 
discovery. We sought to determine the antibacterial activity of a novel antimicrobial peptide, 33 
buwchitin, against Enterococcus faecalis. Buwchitin was identified from a rumen bacterial 34 
metagenome library, cloned, expressed and purified. The antimicrobial activity of the 35 
recombinant peptide was assessed using a broth microdilution susceptibility assay to determine 36 
the peptide’s killing kinetics against selected bacterial strains. The killing mechanism of 37 
buwchitin was investigated further by monitoring its ability to cause membrane depolarization 38 
(diSC3(5) method) and morphological changes in E. faecalis cells. Transmission electron 39 
micrographs of buwchitin treated E. faecalis cells showed intact outer membranes with 40 
blebbing, but no major damaging effects and cell morphology changes. Buwchitin had 41 
negligible cytotoxicity against defibrinated sheep erythrocytes. Although no significant 42 
membrane leakage and depolarization was observed, buwchitin at minimum inhibitory 43 
concentration (MIC) was bacteriostatic against E. faecalis cells and inhibited growth in vitro 44 
by 70% when compared to untreated cells. These findings suggest that buwchitin, a rumen 45 
derived peptide, has potential for antimicrobial activity against E. faecalis. 46 
 47 
Keywords: microbiome, metagenomics, rumen bacteria, antibiotic resistance, antimicrobial 48 
peptides, antimicrobial activity, Enterococcus faecalis. 49 
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 50 
Introduction 51 
Enterococcus faecalis is a non-motile, Gram-positive, facultative anaerobic lactic acid 52 
bacterium of about 0.6-2.0 µm in size, that grows as individual cells, in pairs or as short 53 
multicellular filaments (Leavis et al. 2006, Ch. Schroder et al. 2015). It tolerates a wide variety 54 
of growth conditions, including temperatures between 10-45°C, hypotonic, hypertonic, acidic, 55 
or alkaline environments (Ch. Schroder et al. 2015). E. faecalis is normally a gut commensal 56 
found in many animals and in the environment (Gilmore et al. 2013). It is also a frequent cause 57 
of many serious human infections, including urinary tract infections, endocarditis, bacteremia, 58 
and wound infections alongside Enterococcus faecium (Kau et al. 2005, Gilmore et al. 2013, 59 
Cahill and Prendergast). E. faecalis causes a variety of healthcare associated infections of 60 
which urinary tract infections are the most common (Kau et al. 2005, Hidron et al. 2008, Arias 61 
and Murray 2012, Gilmore et al. 2013). Infections with E. faecalis can be especially 62 
challenging to treat because of their frequent resistance to multiple antibiotics, including 63 
aminoglycosides, and vancomycin, which is considered as drug of last resort for many Gram-64 
positive infections (Baddour et al. 2005, Hollenbeck and Rice 2012, Young et al. 2016). 65 
Vancomycin-resistant enterococci (VRE) are significant opportunistic pathogens in the 66 
hospital environment and often possess a multidrug-resistant phenotype (Chavers et al. 2003, 67 
van Harten et al. 2017) and their potential to spread enterococcal vancomycin resistance to 68 
other species remains a concern (Chang et al. 2003). VRE are also listed as priority pathogens 69 
by the World Health Organization for research and development of new antibiotics (WHO 70 
2017). It is therefore important to develop new drugs for the treatment of enterococcal 71 
infections.   72 
 73 
Continued development of new drugs by the pharmaceutical industry, aided by genomics, high-74 
throughput screening, rational drug design, and novel therapies offer a very promising prospect 75 
of effective bactericidal monotherapy for Enterococci and long-term solutions to VRE 76 
(Eliopoulos and Gold 2001). Antimicrobial peptides (AMPs) are an integral part of the innate 77 
host defense system of many organisms including vertebrates, invertebrates, plants and bacteria 78 
(Wiesner and Vilcinskas 2010), with broad spectrum activity against several groups of 79 
organisms including multidrug resistant bacteria, fungi, viruses and parasites (Jenssen et al. 80 
2006). Due to this, AMPs represent one of the most promising alternatives to antibiotics, and 81 
future strategies for defeating the threat of antimicrobial resistance in bacterial infections might 82 
depend on peptide-based antimicrobial molecules (Czaplewski et al. 2016, O'Neill 2016). 83 
The rumen is one of the most diverse ecosystems in nature, harboring a microbial community, 84 
composed of a complex mixture of bacteria, protozoa, fungi, and viruses (Church 1993, Sirohi 85 
et al. 2012) commonly referred to as the rumen microbiome, and enzymes isolated from this 86 
ecosystem have the potential to possess very unique biochemical properties (Hess et al. 2011, 87 
Ross et al. 2012). Several ruminal bacteriocins have been identified to date, but all of these 88 
bacteriocins are derived from bacteria that can be grown in the laboratory (Russell and 89 
Mantovani 2002, Azevedo et al. 2015). Culture independent methods can be used to assess the 90 
rumen microbiome and increase the repertoire of bacteriocins, and other novel antimicrobials. 91 
It is possible to access and explore the total genetic information of this underexplored, 92 
uncultured fraction of the microbiome associated with any defined ecosystem through the 93 
application of metagenomics (Handelsman et al. 1998, Ekkers et al. 2012), which is the analysis 94 
of the DNA from a microbiome. Direct cloning of genomic or metagenomic DNA also offers 95 
the opportunity to capture genes encoding the synthesis of novel antimicrobials (Schloss and 96 
Handelsman 2003), whether from species with already known antimicrobial properties 97 
(bacteriocin production), or from completely new species. 98 
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Previously, we prospected a 8,448 clone fosmid-based rumen bacterial metagenomic library 99 
generated from cow rumen solid attached bacteria (SAB) for novel antimicrobials, combining 100 
both functional and sequence based metagenomics and in silico mining (Oyama 2015, Prive et 101 
al. 2015). From this work, we identified numerous AMPs and mini proteins. Results of the 102 
activity screens of the identified short AMPs (≤25 AA) were reported elsewhere (Oyama 2015). 103 
One of the longer proteins, buwchitin (71 AA) was selected for further characterization due to 104 
its potential activity against E. faecalis. In this study, we report the potential antimicrobial 105 
activity of buwchitin against E. faecalis. 106 
 107 
Materials and methods 108 
Bacterial strains and vectors 109 
Bacterial strains used for antimicrobial activity testing were provided in-kind by Bath 110 
University. Strains include methicillin sensitive Staphylococcus aureus (MSSA) RN4220, 111 
Escherichia coli K12, Salmonella enterica serovar Typhimurium SL1344, Listeria 112 
monocytogenes NCTC 11994 (serovar 4b) and Enterococcus faecalis JH2-2. E. coli TOP10 113 
(Invitrogen, Carlsbad CA, USA) was used for cloning (to host expression vectors for protein 114 
expression). The pTrcHis TOPO® vector (Invitrogen, Carlsbad, CA, USA) was used to clone 115 
polymerase chain reaction (PCR) products for protein expression. 116 
 117 
Bacteriological media and culture conditions 118 
Mueller Hinton (MH) (Sigma-Aldrich UK) and Luria Bertani (LB) broth and agar (Fisher 119 
Scientific Leicestershire, UK) were used as growth media. When leakage assays were 120 
performed under buffered conditions, 5 mM HEPES (pH 7.2) supplemented with 5 mM glucose 121 
was used (Wu and Hancock 1999). Media were prepared and sterilized according to the 122 
manufacturers’ instructions. Bacterial strains were grown using standard conditions unless 123 
otherwise specified. Broth cultures were incubated at 37oC for 18-20 h with aeration and 124 
cultures on solid media were incubated at 37oC for 18-24 h.  125 
 126 
Identification of antimicrobial genes from fosmid metagenomic library by agar based 127 
functional screening and sequencing analysis 128 
Antimicrobial genes were identified from the fosmid metagenomic library as previously 129 
described (Oyama 2015). Briefly, sterile pin replicators (Molecular Devices Ltd, Berkshire 130 
UK) were used to transfer 2 µl metagenomic clones onto LB agar plates that had been plated 131 
before with 500 µl (OD600nm = 1) of pathogens such as S. aureus, E. coli, Sal. Typhimurium, E. 132 
faecalis and L. monocytogenes. Plates were incubated at appropriate temperatures for 24 h and 133 
zones of clearing around the clones were used to identify clones with inserts encoding 134 
antimicrobials. Putative antimicrobial positive fosmid clones were sequenced using Roche’s 135 
454 pyrosequencing platform. BLASTN (v2.2.28) on NCBI and BioEdit (version 7.1.11) (Hall 136 
1999) were used to edit and trim the vector sequence from the contigs. VecScreen on NCBI 137 
was used to search the sequences for vector contamination. Open reading frames (ORFs) were 138 
determined using the NCBI ORF finder program (Wheeler et al. 2003) and all ORFs with 139 
homology to antimicrobial genes and/or peptides were collated (Table 1). Based on expression 140 
levels and final protein yield, an ORF composed of 71 amino acids and named buwchitin was 141 
further investigated. Here, we report the activity of buwchitin.  142 
 143 
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Amplification of antimicrobial genes 144 
Extracted fosmid DNA (1 µl) from a metagenomic clone containing the buwchitin insert was 145 
used as template for PCR amplification. The buwchitin sequence was deposited in the GenBank 146 
database with accession number KY823515 and predicted to contain a signal peptide, when 147 
analyzed on the SignalP 4.1 server (Petersen et al. 2011). Primers were designed to start and 148 
stop at the first predicted methionine and at the last stop codon respectively in order to conserve 149 
the reading frame and take account of the entire gene of interest. The primers used for the 150 
amplification of buwchitin gene were 5'-ATGAGGCTGTCACACGTTTG-3' (forward primer) 151 
and 5'-TCACCAATCTGTATGGCACCG-3' (reverse primer). Primers were diluted to a stock 152 
concentration of 100 µM and a total volume of 50 µl PCR reaction was set up as follows: 2 µl 153 
DNA template, 1 µl each of the forward and reverse primers (2 µM final concentration), 39.5 154 
µl molecular grade water and 1 µl Titanium® Taq DNA Polymerase (Clonetech- Takara Bio 155 
Europe/SAS, France). Taq polymerase was activated for 1 minute at 95oC, followed by 30 156 
cycles of 95oC for 30 seconds, 68oC for 1.5 minutes, followed by a final extension step at 68oC 157 
for 1.5 minutes. PCR products were verified by electrophoresis on a 1.5% agarose gel using a 158 
1 kb DNA ladder. Gel image was taken after exposure to UV using the Gel DocTM XR+ system 159 
(BIO-RAD Hertfordshire, UK). Subsequently, the band of interest was excised with a sterile 160 
scalpel under a Dark Reader blue transilluminator (Clare Chemical Research Inc. USA) and 161 
DNA was purified and eluted using the QIAquick Gel Extraction Kit (Qiagen, Crawley, UK) 162 
according to manufacturer guidelines. 163 
Cloning of buwchitin gene and confirmation of cloning reaction 164 
Cloning of buwchitin was carried out using the pTrcHis TOPO® TA Expression kit as 165 
described by the manufacturer. Five positive colonies from the transformation were analyzed 166 
for correct size, sequence and orientation of the insert. Selected colonies were cultured 167 
overnight in LB medium containing 100 µg/ml ampicillin and 0.5% glucose, and analyzed by 168 
PCR. Briefly, aliquots (1 ml) were lysed by heating for 10 mins at 95oC in sterile 1.5 ml 169 
microcentrifuge tubes. The cell debris was pelleted by centrifugation at 13,000  g for 2 mins. 170 
The supernatant was used as template for the subsequent PCR. The PCR was set up in a total 171 
volume of 50 µl as follows: 2 µl of template DNA, 1 µl of each gene specific forward primer 172 
(5'-ATGAGGCTGTCACACGTTTG-3') and vector specific reverse primer (5´-173 
GATTTAATCTGTATCAGG-3´), 21 µl molecular grade water and 25 µl MyTaq™ Red Mix 174 
(Bioline, UK Ltd, London UK). Initial Taq activation was performed at 95oC for 1 min, 175 
followed by 35 cycles of 95oC for 15 sec, at insert specific annealing temperature for 15 sec 176 
with an extension step at 72oC for 10 sec, and a final extension step at 72oC for 7 mins and 177 
holding at 4oC. PCR products were verified by electrophoresis on a 1.5% agarose gel using a 178 
500bp DNA ladder. A positive PCR control was also prepared using the control PCR template 179 
(expected size of 750 bp) and primers provided with the pTrcHis-TOPO® expression kit. 180 
Positive transformants were further analyzed by Sanger sequencing using plasmid DNA from 181 
extracted positive transformants as templates. The Xpress™ Forward sequencing primer for 182 
pTrcHis-TOPO® (5´-TATGGCTAGCATGACTGGT-3´) was then used to sequence the insert 183 
and alignments to original sequence orientation was confirmed using BioEdit (Hall 1999). 184 
Expression and purification of His-tagged buwchitin 185 
A single recombinant E. coli colony from a clone confirmed as containing the buwchitin gene 186 
was inoculated into LB broth containing 100 µg/ml ampicillin and grown overnight at 37°C 187 
with aeration and agitation (225-250 rpm). The following day, 1 L of LB broth containing 100 188 
µg/ml ampicillin was inoculated with 20 ml of the overnight culture and incubated at 37°C 189 
under aeration (225-250 rpm). Gene expression was induced at OD600nm = 0.6 with 1 mM IPTG. 190 
Cells were harvested after 4 h by centrifugation (3,000 x g for 10 mins at 4oC) and cell pellets 191 
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were stored at -80oC for subsequent protein purification. Simultaneous purification and 192 
concentration of the buwchitin protein was carried out under native conditions using the 193 
Amicon® Pro Purification System (Merck Millipore Ltd Carrigtwohill, Ireland) following the 194 
manufacturer’s protocol. Protein concentration was calculated as the ratio of absorbance at 280 195 
nm (BioTek’s Epoch™ Multi-Volume Spectrophotometer, (BioTek Instruments, Inc. 196 
Vermont, USA)) to the extinction coefficient absorbance (Abs 0.1% =1 g/l calculated using the 197 
ExPASy ProtParam tool) (Gasteiger et al. 2005). 198 
Determination of minimum inhibitory concentration (MIC) of buwchitin 199 
Vancomycin, Polymyxin B sulfate and ciprofloxacin were purchased from Sigma-Aldrich 200 
(Poole, Dorset, United Kingdom). All stock solutions were dissolved in the appropriate solvent 201 
prior to dilution in sterile distilled water (Andrews, 2001). MICs of buwchitin was measured 202 
by broth microdilution method using two-fold serial dilutions of antimicrobial agents in MH 203 
broth (CLSI. 2012). Buwchitin or comparator agents, vancomycin hydrochloride, polymyxin 204 
B sulfate and ciprofloxacin were added to the wells of a 96-well plate containing bacteria from 205 
overnight culture (adjusted to 1 × 108 CFU/ml) to achieve a final inoculum concentration of 5 206 
× 105 CFU/ml (Cherkasov et al. 2008, Wiegand et al. 2008). MIC was defined as the lowest 207 
concentration of test agent that inhibited visible growth of the organism after 18-24 h of 208 
incubation at 37⁰C.  209 
Bactericidal/bacteriostatic activity of buwchitin 210 
The bactericidal or bacteriostatic activity of buwchitin against E. faecalis was measured at MIC 211 
concentration using optical density measurements. An increase in both cell mass and cell 212 
number can readily be estimated by measuring the turbidity of a cell suspension using a 213 
spectrophotometer, thereby offering a rapid and sensitive alternative to cell counting (Dalgaard 214 
and Koutsoumanis 2001, Madrid and Felice 2005). This method has been shown to produce 215 
comparable results to plate counting, flow cytometric and green fluorescence viability analyses 216 
methods (Lehtinen et al. 2006). In a 96 well plate, buwchitin was added to cells in mid-217 
logarithmic phase (1 x 106 CFU/ml, OD600nm of ≤0.2) in MH broth and serially diluted as 218 
previously described. Plates were incubated at 37˚C in a microplate incubator shaker. Wells 219 
without antimicrobial agents were used as growth control while wells with MH broth alone 220 
served as negative control. The rate of kill was calculated as a percentage (OD600nm) of 221 
surviving cells over a 24 h period (Lehtinen et al. 2006, Hazan et al. 2012). The percentage of 222 
viable cells was normalized to 100% for the growth control (cells without antibiotic treatment). 223 
 224 
Erythrocyte leakage assay  225 
The ability of buwchitin to lyse red blood cells was assessed in a 96 well plate using 226 
defibrinated sheep blood (Oxoid Ltd Hampshire, UK). Sheep red blood cells (RBC) washed 227 
and diluted (4%) in phosphate buffered saline (35 mM PBS) (pH 7.3) were treated with 228 
buwchitin at different concentrations and incubated at 37°C for 1 h. Triton X-100 (0.1% causes 229 
100% cell lysis) served as a positive control. Absorbance (OD450nm) of the supernatant (70 µl) 230 
from each well of the plate was measured to detect hemoglobin leakage from the erythrocyte 231 
cytoplasm and obtained results were used to determine the percentage hemolysis given that the 232 
0.1% Triton X-100 represented 100% lysis after normalizing auto-hemolysis (PBS only 233 
treatment). 234 
 235 
Inner membrane depolarization assay (diSC3(5) method) 236 
The ability of buwchitin to disrupt the electrochemical potential across the bacterial 237 
cytoplasmic membrane was measured by determining the amount of the membrane-associated 238 
probe, 3,3′-dipropylthiadicarbocyanine iodide [diSC3(5)] released from the cytoplasm. (Wu et 239 
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al. 1999, Lee et al. 2004). Briefly, mid-logarithmic phase (OD600nm = 0.2) E. faecalis cells 240 
were washed and resuspended to an OD600nm of 0.05 in 5 mM HEPES-glucose buffer, pH 7.2. 241 
In a 96-well plate, the cell suspension was incubated with 100 mM potassium chloride (KCl) 242 
and 0.4 mM 3,3′-dipropylthiadicarbocyanine iodide [diSC3(5)] until a stable reduction of 243 
fluorescence (excitation λ 622 nm, emission λ 670 nm) was achieved (approximately 1 h). The 244 
KCl was added to equilibrate the cytoplasmic and external K+. After 1 h, buwchitin, positive 245 
control agent (0.1% Triton X-100) or negative control agent (untreated cells) were added to the 246 
cells in the wells. The plate was further incubated at 37°C with shaking while fluorescence was 247 
continuously monitored (excitation λ 622 nm, emission λ 670 nm) upon addition of peptide at 248 
2 to 5 minute intervals for 2 h. 249 
 250 
Transmission electron microscopy (TEM) 251 
Exponential phase cultures of E. faecalis grown in MH broth were washed and resuspended to 252 
an OD600nm of 0.2 in 10 mM PBS. The cell suspensions (1 ml) were incubated at 37°C with 253 
buwchitin at 1x MIC concentration in microcentrifuge tubes. To investigate possible changes 254 
in cell morphology following exposure to buwchitin, samples were removed at 1 h and 24 h 255 
after exposure and prepared for TEM as previously described (Huws et al. 2013). Briefly, 256 
samples were fixed with 2.5% (v/v) glutaraldehyde, after which they were post-fixed with 1% 257 
(w/v) osmium tetroxide. Fixed samples were then stained with 2% (w/v) uranyl acetate and 258 
Reynold's lead citrate and observed using a JEOL JEM1010 TEM (JEOL Ltd, Tokyo, Japan) 259 
at 80 kV. 260 
 261 
Molecular modelling of peptide 3D structures 262 
Structural modeling of buwchitin was completed using the PHYRE2 web portal (Kelley et al. 263 
2015). Results were visualized using the PyMOL v1.7.6 program (Schrödinger 2010). The 264 
biophysical properties of buwchitin were predicted on the antimicrobial peptide database 265 
(APD2) (Wang et al. 2009). 266 
 267 
Statistical analysis 268 
Two-way analysis of variance (ANOVA) with factors ‘antimicrobial treatments’ and ‘time’ 269 
was performed to determine whether there were significant changes in cell viability and 270 
membrane depolarization before and after treatment (Harmon 2011). This was followed by 271 
post-hoc multiple comparisons using Tukey’s HSD (Honestly Significant Difference) test 272 
(Bender and Lange 2001, Feise 2002, Harmon 2011). Alpha (α) levels were set at P < 0.05. 273 
 274 
Results 275 
Sequencing, cloning, expression and purification using in vivo expression systems 276 
The buwchitin gene was successfully PCR amplified using DNA from the fosmid clone, SAB 277 
PL27 L10/66. Bands of the correct size (expected size of 216 bp) were excised from the gel 278 
before proceeding to cloning. Electrophoresis results confirmed that the transformants carried 279 
the gene of the correct size, which was also confirmed by Sanger sequencing. The antimicrobial 280 
protein was expressed with an N-terminal 6xHis-Tag in E. coli to facilitate purification and 281 
investigation of its biochemical properties. Preliminary protein expression assay indicated that 282 
protein expression was optimal 4 h after induction (data not shown). SDS PAGE analysis of 283 
negative expression control (E. coli Top10 cells without plasmid) showed no protein expression 284 
bands while positive expression control (E. coli Top10 cells with pTrcHis-TOPO/lacZ) showed 285 
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expression of the protein with a correct size of 40 kDa (data not shown). Cultivation of 286 
buwchitin transformants were scaled up to a total volume of 1 L to produce cell pellets for 287 
protein purification. Recombinant proteins were purified in their native conditions to preserve 288 
their activity (Karakus et al. 2016). Figure 1 shows the SDS-PAGE analysis of the purification 289 
fractions for buwchitin. The purification protocol reproducibly yielded a total of ~0.8 mg of 290 
purified protein per liter of culture.  291 
Antimicrobial and cytotoxic activity of buwchitin 292 
Buwchitin was active against E. faecalis with an MIC of 100-200 µg/ml (Table 2). It also 293 
showed some inhibition of E. coli growth (observed in growth curves), but no detectable MIC 294 
at the highest concentration tested. This may account for the low level of expression of 295 
buwchitin in the E. coli expression host. The highest concentration of buwchitin tested was 400 296 
µg/ml due to low levels of protein expression and/or yield of purified protein. The killing 297 
activity of buwchitin against E. faecalis was calculated as a percentage (OD600nm) of surviving 298 
cells compared to the growth control. Only about 30 ± 1.4% surviving E. faecalis cells 299 
remained after a 24 h incubation period (P < 0.05). It would seem that buwchitin had a 300 
bacteriostatic effect against E. faecalis cells (Figure 2) as no change in E. faecalis cell density 301 
was observed over an incubation period of 24 h. Very little hemolytic effect (12.81 ± 0.02%) 302 
was observed when sheep red blood cells were treated with buwchitin at a concentration twice 303 
as high as the MIC determined for E. faecalis (Table 3). 304 
Buwchitin did not induce membrane depolarization in E. faecalis in the first 2 h of treatment. 305 
To determine whether the loss of viability in E. faecalis following exposure to buwchitin was 306 
accompanied by or was a result of changes in cell morphology and cell wall ultrastructure, 307 
TEM was performed. Electron micrographs of untreated E. faecalis at 1 h and 24 h reveal intact 308 
healthy cells. Electron micrographs of buwchitin treated E. faecalis cells at 1 h showed intact 309 
outer membranes with blebbing but no major damaging effects and cell morphology changes. 310 
In contrast, micrographs of buwchitin treated E. faecalis cells at 24 h revealed several changes 311 
in cell morphology including cell lysis and detachment of the cell interior from the cell 312 
envelope (Figure 3). 313 
 314 
Structural modelling of buwchitin 315 
Modelling and visualization of the 3D conformation of buwchitin using PHYRE2 (Kelley et 316 
al. 2015) and PyMOL v1.7.6 (Schrödinger 2010) respectively, suggested that buwchitin is 317 
composed of a compact, all-helical, structure with major amphipathic helix connecting two 318 
smaller helices (Figure 4). The amphipathic helix agrees with a common structural feature of 319 
AMPs as the dual hydrophilic/hydrophobic nature allows the interaction and embedding of 320 
cellular membranes (Hancock and Sahl 2006). As predicted by the APD2 database, buwchitin 321 
(71AA) is positively charged (+9), has a total hydrophobicity ratio of 29% and total Arginine 322 
and Lysine ratio of 19%. 323 
 324 
Discussion 325 
Many currently used antibiotics were discovered by screening soil microorganisms that can be 326 
grown in the laboratory using standard microbial techniques for their antimicrobial activity 327 
(Ling et al. 2015). However, as natural product resources are practically inexhaustible, and 328 
approximately 99% of all species in external environments require more complex growth 329 
conditions that those provided using standard cultivation techniques, the majority of the world's 330 
microbial biodiversity remains to be explored (Harvey 2007, Berdy 2012, Lewis 2013). Several 331 
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recent studies already suggest that new organisms such as uncultured bacteria are likely to 332 
harbor new antimicrobials (Degen et al. 2014, Doroghazi et al. 2014, Gavrish et al. 2014, 333 
Wilson et al. 2014) and underexplored complex microbial communities, including the rumen, 334 
very likely represent rich sources of novel antimicrobials. These microbiomes have the 335 
potential to revive the platform of natural product discovery in a new culture-independent 336 
perspective, unbiased by the culturing aptitude of microbial species (Lewis 2012, McCann et 337 
al. 2014, Kang et al. 2015). The potential for application of metagenomics to biotechnology 338 
seems endless as functional screens can be used to identify new enzymes, antibiotics and other 339 
biological agents in libraries from diverse environments (Gillespie et al. 2002, Lorenz and 340 
Schleper 2002, Piel 2002, Voget et al. 2003, Berdy 2012). 341 
 342 
In this study, we used a combination of functional and sequence based metagenomic screening 343 
strategies to prospect the rumen microbiome for novel antimicrobials as both strategies present 344 
advantages and limitations (Uchiyama and Miyazaki 2009). Whereas, sequence homology 345 
based analysis allows for the identification of new enzymes from a range of environments, it 346 
requires a certain sequence similarity to members from known gene families, therefore limiting 347 
novelty. Functional screening of metagenomic libraries on the other hand, does not depend on 348 
previous sequence knowledge and therefore has the potential to discover novel classes of genes 349 
coding for desired functions without depending on their sequence similarity to already known 350 
genes (Ferrer et al. 2009, Simon and Daniel 2009). We identified a novel antimicrobial gene, 351 
buwchitin, from the rumen microbiome and sought to express and characterize its antimicrobial 352 
activity against E. faecalis. Firstly, a fosmid-based cow rumen metagenomic clone library 353 
created from the solid attached bacteria of rumen content was functionally screened for 354 
antimicrobial activity. Clones with antimicrobial activity were subsequently sequenced to 355 
identify genes potentially involved in the antimicrobial activity observed in functional screens. 356 
Buwchitin, which was identified as a potential antimicrobial gene, was then expressed and 357 
further tested for antimicrobial activity. Buwchitin is a cationic (charge of +9), α-helical 358 
peptide (as predicted by 3D modelling), 71 amino acids in length and has a molecular weight 359 
of 8.35 kDa. Expression of buwchitin yielded on average 0.8 mg of purified protein per liter of 360 
culture. This relatively low yield may be due to the inhibitory effects of buwchitin on E. coli 361 
growth. However, this yield falls in the range reported in literature where concentrations of 362 
0.5-2.5 mg/ml (Guerreiro et al. 2008), and 0.8 mg/ml (Zorko et al. 2009, Pei et al. 2014) were 363 
retrieved from 1 L cultures by different approaches using Ni-NTA columns. It may be useful 364 
to explore alternative expression systems, such as Pichia sp. or Aspergillus sp. to improve the 365 
yield of the protein. 366 
 367 
Buwchitin was active against E. faecalis JH2-2 with an MIC of 100-200 µg/ml. This MIC is 368 
high when compared to antimicrobial proteins isolated and expressed using similar methods in 369 
other studies (Zorko et al. 2009, Elhag et al. 2017). Buwchitin (at MIC concentration) inhibited 370 
growth of E. faecalis cells with no change in E. faecalis cell density over a 24 h incubation 371 
period and has a minimum bactericidal concentration (MBC) of 200-400 µg/ml, suggestive of 372 
a bacteriostatic killing activity. Although most antimicrobial peptides are bactericidal 373 
(Hancock 2001, Reddy et al. 2004, Lohner 2017), many examples of bacteriostatic 374 
antimicrobial peptides exist in literature (Mine et al. 2004, Choi et al. 2016). For example, the 375 
human β-defensin 2 (hBD-2) is bacteriostatic against S. aureus only at concentrations as high 376 
as 100 µg/ml (Harder et al. 1997, Jung et al. 2011). Another example of a bacteriostatic 377 
antimicrobial peptide is the human lactoferricin (LfcinH) (Gifford et al. 2005). Furthermore, 378 
most antibacterials are potentially both bactericidal and bacteriostatic depending on bacterial 379 
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pathogen (Pankey and Sabath 2004). Further investigations into the mechanism underlying the 380 
bacteriostatic action of buwchitin would be necessary to come to a final conclusion about its 381 
accurate classification. Buwchitin had minimal hemolytic activity against sheep erythrocytes, 382 
suggesting that buwchitin may have selective activity against microbial cells. Despite these 383 
encouraging results, it will be necessary to carry out cytotoxicity assays on human and other 384 
mammalian cell lines to determine whether buwchitin can induce apoptosis and necrosis in 385 
cells (Paredes-Gamero et al. 2012). Very little or no membrane depolarization was observed in 386 
E. faecalis cells treated with buwchitin and TEM images of buwchitin treated cells showed 387 
intact outer membrane and very little changes in cell morphology after 1 h of treatment. Only 388 
after 24 h of treatment were large vacuoles in the cytoplasm and separation of the cell envelop 389 
observed. Given the low depolarizing activity of buwchitin, it would seem that membrane-390 
destabilizing activity alone does not explain the antimicrobial activity of buwchitin. It is known 391 
that poly-cationic AMPs bound to teichoic acids including lipoteichoic (LTA) and wall teichoic 392 
acids (WTA) build a poly-anionic ladder and may initiate bacterial killing by facilitating the 393 
entry of peptides into the cytoplasmic membrane without membrane depolarization 394 
(Schneewind and Missiakas 2014, Malanovic and Lohner 2016). Further investigation into 395 
buwchitin teichoic acid binding and other mode of action studies are required to gain insights 396 
into its mechanism of action and the events leading to cell death.                                                                                                 397 
Buwchitin is positively charged and has an amphiphilic structure with 29% hydrophobic 398 
residues as has been observed for many antimicrobial peptides (Hancock and Sahl 2006). This 399 
positive charge greatly facilitates the accumulation of AMPs at the polyanionic microbial cell 400 
surfaces and may be sufficient for antimicrobial action (Hancock and Sahl 2006), thus 401 
perturbing the membrane integrity. Some cationic peptides have been shown to translocate or 402 
form multimeric transmembrane channels promoting the membrane depolarization, which 403 
seems to contribute to their activity (Shai 1999, Bhattacharjya and Ramamoorthy 2009) at 404 
higher concentrations. The amphipathic nature of the predicted peptide structure and the 405 
observations in the TEM images is in agreement with this type of interaction, indicating that 406 
although buwchitin is not membrane destructive, it may interact with components of the cell 407 
envelop such as the enterococcal polysaccharide antigen. The formation of vacuoles in the 408 
cytoplasm also appear to support this idea. Still, at the current stage, it remains difficult to say 409 
which of the known membrane interaction and disruption models (i.e. barrel stave, carpet 410 
models, or micellar aggregate model) explains the activity of this peptide without further 411 
experimental evidence.  412 
 413 
Further studies remain to be performed to enhance the antimicrobial phenotype of buwchitin. 414 
One potential strategy to improve the antimicrobial activity of buwchitin is the pepscan 415 
technology, in which shorter active fragments and optimized amino acid substitutions and/or 416 
modifications are identified by a scanning approach. These active peptide fragments identified 417 
by pepscan can then be SPOT-synthesized on cellulose membranes and systematically screened 418 
for antimicrobial activity (Hilpert et al. 2007, Winkler et al. 2009). The use of pepscan mapping 419 
and SPOT arrays has been shown to be useful for simultaneous optimization of peptides to 420 
generate new sequences that possess a variety of therapeutic and biological properties (Chico 421 
et al. 2010, Haney et al. 2015, Merino-Gracia et al. 2016, Ortega-Villaizan et al. 2016). Peptide 422 
improvements that might result from the pepscan technology might provide buwchitin 423 
derivatives with greater antimicrobial activity, similar to what has been achieved for other 424 
peptides in the literature (Knappe et al. 2016, Mikut et al. 2016). An evaluation of MICs against 425 
a panel of different bacterial species and in vitro stability studies in the presence of plasma or 426 
serum would also be beneficial. To explore the possible therapeutic relevance of buwchitin, 427 
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further in vitro cytotoxicity studies and in vivo studies with acute toxicity in mice at 428 
concentrations above the MIC would be required. 429 
 430 
In conclusion, the data we generated and present here suggest that we discovered a novel rumen 431 
protein, buwchitin, with potential antimicrobial properties. It is furthermore possible that with 432 
substantial modification, this AMP might qualify as a potential antimicrobial agent for the 433 
treatment of E. faecalis infections, which would favor further investigation of the protein. This 434 
study also highlights the enormous value of prospecting the rumen microbiome, and other 435 
microbial communities for novel compounds to expand our limited antimicrobial drug toolbox. 436 
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Table 1. ORFs with homology to antimicrobial (biosynthetic) protein coding genes in rumen metagenome fosmids. All ORFs are from contig 
1 of each fosmid and are in the 5’-3’ direction. 
 
 
 
 
 
 
Fosmid Plate 
ID/ORF 
 
 
Gene name 
Protein size 
(AA) Most similar homolog (e-value) Putative function 
Identity 
(overlapped AA)/% 
similarity 
SABPL5 C17/11 
 
 
 
 
 
Gene 6 184 
Prevotella ruminicola 23 
WP_013063463.1 (3e-104) 
4'-phosphopantetheinyl transferase 
family protein  
Synthesis of unusual molecules including 
polyketides, atypical fatty acids, and 
antibiotics  140/184(76% 
  
 
  
Butyrivibrio crossotus CAG:259 
WP_021960962.1 (2e-33) 
putative biosurfactants production 
protein 58/161(36% 
SABPL12(1) C3/9 
 
 
Gene 17A 
350 Prevotella sp.  CDD20257.1(0.0) 
3-dehydroquinate synthase  
DHQS represents a potential target for the 
development of novel and selective 
antimicrobial agents 250/346(72%) 
SABPL12(1) C3/50 
 
 
Gene 17B 80 
Pseudomonas putida S16 NP_744149.1 
(1.4) 
Colicin V production protein 
19/61(31%) 
SABPL27 L10/66 
 
 
 
Buwchitin 71 
Streptomyces mobaraensis 
WP_004942604.1 e-value 5.0 
penicillin amidase   
Penicillin biosynthesis and metabolism 16/43(37%) 
SABPL27 L10/73 
 
 
 
Gene 68 68 
Ornithinibacillus scapharcae 
YP_004810705.1 e value 8.4 
beta-lactam antibiotic acylase   
Penicillin biosynthesis and metabolism 22/63(35%) 
19 
 
Table 2 Minimum inhibitory concentration (MIC) of buwchitin and comparator antimicrobial agents (n = 6)), > (precedes the highest 
concentration tested). Highest concentration of buwchitin tested is 400 µg/ml due to low protein yield. 
Peptide ID 
 
MICs (µg/ml) 
Sal. typhimurium E. coli S. aureus E. faecalis 
Polymyxin B sulfate  1.95 1.95 250 31.25 
Ciprofloxacin  0.12 0.06 >250 62.5 
Vancomycin hydrochloride  250 125 0.98 62.5 
Buwchitin  >400 >400 >400 100-200 
20 
 
Table 3. Hemolytic activity of buwchitin against sheep erythrocytes E. faecalis cells 
resuspended and diluted (4%) in PBS were treated with buwchitin (1x MIC) or 0.1% (v/v) 
Triton X-100 and hemolysis was monitored at OD450nm at 1 h after incubation at 37
oC, (values 
from three independent replicates and showing the standard deviation). 
 
Concentration (µg/ml) % hemolysis 
400 12.81 ± 0.02 
200 9.69 ± 0.09 
100 5.23 ± 0.08 
50 4.12 ± 0.06 
25 4.15 ± 0.06 
12.5 3.08 ± 0.03 
6.25 2.80 ± 0.02 
3.125 3.11 ± 0.06 
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Figure Legends 690 
Figure 1. SDS-PAGE analysis of purification steps of buwchitin protein expressed in E. coli 691 
TOP10 cells on a 20% denaturing polyacrylamide gel (4 h after induction with 1 mM IPTG). 692 
Lane 1: protein molecular weight marker, Lane 2: cell lysate, Lane 3: supernatant, Lane 4: 693 
Wash step, Lane 5: eluted buwchitin protein. The arrow indicates band of purified protein of 694 
interest. Expected size is 8.35 (±3-4 kDa from His-tag). 695 
Figure 2 Growth rate of E. faecalis in presence of antibacterial agents. Growth rate was 696 
determined by monitoring cell density at OD600nm in three independent measurements at 1x 697 
MIC concentration. Error bars represent the standard deviation. 698 
Figure 3. Representative transmission electron micrographs of E. faecalis. A) Untreated E. 699 
faecalis cells at 1 h. B) Buwchitin treated cells (200 µg/ml) at 1 h. C) Untreated E. faecalis at 700 
24 h. D) Buwchitin treated cells (200 µg/ml) at 24 h. Scale bars on micrographs.  701 
Figure 4. Structural model of buwchitin (grey) in cartoon and surface representation. Side 702 
chains of selected amino-acid colored according to atom type (N: blue; C: white; O: red). The 703 
N- terminus (Nt) and C- terminus (Ct) is also shown. Figure prepared using PyMol 704 
(Schrödinger 2010). 705 
 706 
 707 
 708 
  709 
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Figure 1. SDS-PAGE analysis of purification steps of buwchitin protein expressed in E. coli 
TOP10 cells on a 20% denaturing polyacrylamide gel (4 h after induction with 1 mM IPTG). 
10 µl and 20 µl molecular weight markers and proteins loaded in gel respectively. Lane 1: 
protein molecular weight marker, Lane 2: cell lysate, Lane 3: supernatant, Lane 4: Wash step, 
Lane 5: eluted buwchitin protein. The arrow indicates band of purified protein of interest. 
Expected size is 8.35 (±3-4 kDa from His-tag). 
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Figure 2. Growth rate of E. faecalis in presence of antibacterial agents. Growth rate was 
determined by monitoring cell density at OD600nm in three independent measurements at 1x 
MIC concentration. Error bars represent the standard deviation. 
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Figure 3. Representative transmission electron micrographs of E. faecalis. A) Untreated E. 
faecalis cells at 1 h. B) Buwchitin treated cells (200 µg/ml) at 1 h. C) Untreated E. faecalis at 
24 h. D) Buwchitin treated cells (200 µg/ml) at 24 h. Scale bars on micrographs. 
25 
 
 
Figure 4. Structural model of buwchitin (grey) in cartoon and surface representation. Side 
chains of selected amino-acid colored according to atom type (N: blue; C: white; O: red). The 
N- terminus (Nt) and C- terminus (Ct) is also shown. Figure prepared using PyMol 
(Schrödinger 2010).  
